Abstract 16572: High Sensitive Cardiac Troponin T Predicts Long-Term Risk of Incident HF Independent of Cardiovascular Risk Factors and Cardiac Structure/Function in a Multi-Ethnic Population Without CVD: The Multi-Ethnic Study of Atherosclerosis
Introduction: Although small elevations of high sensitive cardiac troponin T (hs-cTnT) have been associated with incident heart failure (HF), the robustness of this finding across a large spectrum of age in a contemporary ethnically diverse population free of cardiovascular disease (CVD) is unknown.
Hypothesis: Among middle age to older adult MESA study participants with a baseline cardiac magnetic resonance (CMR) study, hs-cTnT level will identify risk of incident HF independent of demographics, risk factors and CMR structural findings.
Methods: MESA includes 6814 adults aged 45-84 and free of known CVD. hs-cTnT was measured from previously frozen plasma in 99.5% using the Cobas e601 (Roche Diagnostics). 4986 also had baseline CMR exams and were included in this analysis. 3341 (67%) of participants had a hs-cTnT ≥ 3 ng/L (limit of detection [LOD]). hs-cTnT was considered as a continuous measure and as 5 categories (<LOD, and 4 additional categories ≥LOD). Incident HF was compared across hs-cTnT categories using the log-rank test, and adjusted associations were estimated using Cox regression.
Results: Mean age was 61.5±10.1, with 52.4% women, 39.1% Caucasians, 13.1% Chinese-Americans, 25.7% African-Americans, and 22.2% Hispanics. There were 177 incident HF events during a mean follow-up of 12.2 years. Higher concentrations of hs-cTnT were associated with increased incidence of HF (Figure). After adjusting for demographics, CVD risk factors, renal function, left ventricular mass and EF, hs-cTnT remained associated with HF, with a 3.5-fold higher risk for those with hs-cTnT >8.8 ng/L compared to <LOD (HR=3.47, 95%CI 1.80-6.68). These associations did not differ by gender (p=0.4) nor race (p=0.3)
Conclusions: hs-cTnT level predicts incident HF in a CVD-free population-based cohort across a broad spectrum of age and ethnic diversity even when accounting for sensitive measures of cardiac structure and function by CMR.
Author Disclosures: S. Seliger: Research Grant; Significant; Roche Diagnostics. Consultant/Advisory Board; Significant; Abbvie. S. Hong-Zohlman: Other Research Support; Modest; Roche Diagnostics. J. deLemos: Other Research Support; Significant; Roche Diagnostics; Abbot. Consultant/Advisory Board; Significant; Radiometer; Siemens Healthcare; Roche Diagnostics. R. Christenson: Research Grant; Modest; Roche Diagnostics. Speakers Bureau; Modest; Roche Diagnostics; Siemens Diagnostics. Consultant/Advisory Board; Modest; Roche Diagnostics, Siemens Diagnostics, BD Life Sciences, Phillips. J. Lima: None. A. Bertoni: None. L.B. Daniels: Research Grant; Modest; Siemens Healthcare. Speakers Bureau; Modest; Roche Diagnostics. Consultant/Advisory Board; Modest; diaDexus. C. deFillippi: Other Research Support; Significant; Roche Diagnostics, Abbott, Critcial Diagnostics. Honoraria; Modest; Roche Diagnostsics, Thermo Fisher. Honoraria; Significant; Siemens Health care, Ortho Diagnostics, Radiometer.
- © 2016 by American Heart Association, Inc.